Apoptosis

Apoptosis is an autonomous, genetically controlled, orderly death of cells to maintain the stability of the internal environment. Unlike necrosis, apoptosis is not a passive process, but an active one, involving the activation, expression and regulation of a series of genes, and it is not a phenomenon of autologous damage under pathological conditions, but an active death process for better adaptation to the survival environment. Apoptosis is a fundamental biological phenomenon of cells and plays a necessary role in the removal of unwanted or abnormal cells in multicellular organisms. It plays an important role in the evolution of organisms, the stability of the internal environment, and the development of several systems. Apoptosis is not only a specific type of cell death, but also has important biological significance and complex molecular biological mechanisms.

Cat. No.	Product name
BP10953	Inavolisib
BP10953	GDC-0077 is an orally available and selective inhibitor of PI3Kα (IC50=0.038 nM). GDC-0077 is more selective for mutant versus wild-type PI3Kα. GDC-0077 exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3.
BP10819	INCB-057643
BP10819	INCB057643 is a potent, selective and orally bioavailable BET inhibitor.
BP10939	Indibulin
BP10939	Indibulin is a synthetic small molecule with antimitotic and potential antineoplastic activities.Indibulin an orally applicable inhibitor of tubulin assembly, shows potent anticancer activity with a minimal neurotoxicity. Indibulin reduces inter-kinetochoric tension, produces aberrant spindles, activates mitotic checkpoint proteins Mad2 and BubR1, and induces mitotic arrest and apoptosis.
BP10186	INDY
BP10186	INDY is a potent and ATP-competitive Dyrk1A and Dyrk1B inhibitor with IC50s of 0.24 μM and 0.23 μM, respectively. INDY binds in the ATP pocket of the enzyme and has a Ki value of 0.18 μM for Dyrk1A. INDY sharply reduces the self-renewal capacity of normal and tumorigenic cells in primary Glioblastoma (GBM) cell lines and neural progenitor cells.
BP10348	Inebilizumab
BP10348	Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research.
BP10699	Inecalcitol
BP10699	Inecalcitol is the growth inhibitor of human breast cancer cells. Inecalcitol is a unique vitamin D3 analog with Kd of 0.53 nM.
BP10698	Inecalcitol
BP10698	Inecalcitol (TX 522), a unique vitamin D3 analog, is an orally active vitamin D receptor (VDR) agonist with a Kd of 0.53 nM. Inecalcitol can induce cell apoptosis and has potent anticancer activities.
BP10742	Infliximab
BP10742	Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.
BP10004	INH6
BP10004	INH6, an effective Hec1 inhibitor, selectively disrupts the Hec1/Nek2 interaction and induces chromosome mis-alignment.
BP10448	Irbesartan
BP10448	Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease.
BP10965	Isobavachalcone
BP10965	Isobavachalcone is a chalcone constituent of Angelica keiskei, has potent anti-inflammatory activity, possible can ameliorate neuronal injury in brain diseases associated with inflammation.
BP10660	Isokaempferide
BP10660	Isokaempferide shows hepatoprotective, antiproliferative, and anti-inflammatory effects, the anti-inflammatory effects can be explained, at least in part, by reducing neutrophil degranulation, myeloperoxidase activity, mediators as well as TNF-alpha secretion. Isokaempferide is used as a bronchodilator, can induce relaxation of guinea-pig isolated trachea.
BP10163	Isolongifolene
BP10163	Isolongifolene has antioxidant, anti-inflammatory, anticancer and neuroprotective properties. Isolongifolene is a tricyclic sesquiterpene isolated from Murraya koenigii. Isolongifolene attenuates Rotenone-induced oxidative stress, mitochondrial dysfunction and apoptosis through the regulation of P13K/AKT/GSK-3β signaling pathways.
BP10923	Isoscoparin
BP10923	Isoscoparin is derived from Gentiana algida Pall with antioxidant and anti-adipogenic activities. Isoscoparin can be used in stuides about the prevention and treatment of obesity.
BP10514	Isosilybin A
BP10514	Isosilybin A is a partial PPARγ agonist, it significantly induced ABCA1 protein expression, it inhibited both monophenolase (IC50=1.7-7.6μM) and diphenolase (IC50=12.1-44.9μM) of tyrosinase. Isosilybin A shows anti-angiogenic efficacy, it has anti-prostate cancer (PCA) activity that is mediated via cell cycle arrest and apoptosis induction.
BP10663	ISRIB (trans-isomer)
BP10663	ISRIB (trans-isomer), the trans-isomer of ISRIB, is a effective and specific PERK inhibitor (IC50: 5 nM).
BP10377	Itacitinib
BP10377	Itacitinib is an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic activity.
BP10357	ITK inhibitor 2
BP10357	ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor , with an IC50 of 2 nM.
BP10809	Jaceosidin
BP10809	Jaceosidin has anti-oxidative activity. Jaceosidin has anti-inflammatory activity, also a microglial inhibitor with anti-neuroinflammation activity. aceosidin has anticancer activity, modulates the ERK/ATM/Chk1/2 pathway, leading to inactivation of the Cdc2-cyclin B1 complex, followed by G2/M cell cycle arrest in endometrial cancer cells. Jaceosidin has immunosuppressive effect through inhibiting T cell proliferation and activation, which is closely associated with its potent down-regulation of the IFN-γ/STAT1/T-bet signaling pathway. The pharmacokinetics of Jaceosidin may be dramatically affected by polymorphic CYP1A2, UGT1A1, and UGT1A7 responsible for the metabolism of Jaceosidin or by the coadministration of relevant CYP1A2 or UGT inhibitors or inducers.
BP10973	JAK1-IN-4
BP10973	JAK1-IN-4 is a selective JAK1 inhibitor (IC50s: 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively). JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC50, 227 nM).